Human Genome Sequencing Drops Below $100: A Million-Fold Cost Reduction in 25 Years

The $100 Genome: A Historic Milestone

San Diego startup Element Biosciences has reportedly achieved the $100 human genome milestone in February 2026. Starting from approximately $100 million for the Human Genome Project in 2000, the cost has fallen one million-fold in roughly 25 years.

A Cost Trajectory That Defies Moore's Law

• 2000: Human Genome Project — ~$100 million
• 2014: $1,000 genome achieved
• 2026: Sub-$100 genome achieved

Moore's Law predicts roughly a 32,000x improvement in chip density over 25 years. Genomic sequencing costs have fallen 1,000,000x—31 times faster. This extraordinary cost compression is the result of competing sequencing chemistries, improved optical systems, and computational advances in base-calling algorithms.

What the $100 Genome Unlocks

At this price point, whole-genome sequencing becomes viable for mass-market healthcare:

• Personalized medicine tailored to individual genetic profiles
• Routine newborn genome screening at birth
• Affordable liquid biopsies for early cancer detection
• Population-scale genomics research at unprecedented speed and breadth

Challenging Illumina's Dominance

Element Biosciences has achieved this by developing more efficient sequencing chemistry and optical systems—directly challenging Illumina, which has long dominated the sequencing equipment market. This competitive pressure is accelerating cost reductions across the industry.

The implications extend well beyond healthcare—into agriculture, forensics, drug discovery, and synthetic biology. The $100 genome may be the inflection point at which genomic data becomes as accessible as a consumer product, transforming how we understand human health and disease.